|
|
 |
Aβ Fibrils Drive Oligomer Formation, New Model Suggests
24 May 2013. As attention shifts toward free-floating Aβ oligomers as the prime molecular culprits in AD, there is still plenty of confusion over the role of fibrillar amyloid...
|
| |
|
Finally, Therapies Targeting Huntingtin Poised for Clinic
24 May 2013. Twenty years after the identification of the mutant gene that causes Huntington’s disease, scientists are ready to take therapies that target it into human trials...
|
| |
|
A Protein-Based Study of Parkinsonism’s Incidence
24 May 2013. In a study, scientists included rare types of parkinsonism and categorized them by their underlying proteinopathy...
|
| |
|
Bexarotene Revisited: Improves Mouse Memory But No Effect on Plaques
23 May 2013. Researchers reported in 2012 that the cancer drug bexarotene swiftly cleared amyloid-β and restored memory in transgenic mouse models of Alzheimer's disease...
|
| |
GO TO ALL RESEARCH NEWS  |
|
|
 |
|
|
In the spotlight
|
 |
Model Says Amyloid Fibrils Nucleate New Oligomers
|
 |
 |
Plaques were once seen as the toxins of Alzheimer’s disease, but recent data point to free-floating Aβ oligomers. Now, researchers in the U.K. and |
Sweden put both into the same equation. Their new model, praised for its careful science, proposes that oligomers form through secondary nucleation on existing fibrils. This means that even if fibrils themselves are not that harmful to the brain, they can drive production of the Aβ species now believed to be most menacing. Does this explain why Aβ oligomers lurk around amyloid plaques in the AD brain? Read the full story. Image courtesy of PNAS and Tuomas Knowles
|
|
|
|
|
Bexarotene Redux: Mouse Memory Improves, Plaques Remain
|
|
 Mouse hippocampus |
A 2012 Science paper set the Alzheimer’s field (and the popular press) abuzz by claiming that the cancer drug bexarotene rapidly eliminated amyloid-β plaques and rescued memory deficits in transgenic mouse models of AD. Now, four independent research groups report being unable to reproduce that plaque clearance. Three of the |
new reports confirm that bexarotene improves memory and lowers soluble Aβ in the brain. What does this mixed news mean for planned clinical trials of bexarotene? Read the full story. Image courtesy of Wikimedia Commons |
|
|
|
|
Human Stem Cells Cloned by Somatic Cell Nuclear Transfer
|
|
 Click to watch video of cloned heart cells |
Scientists have finally succeeded in making human embryonic stem cells via somatic cell nuclear transfer. These stem cells can develop into any tissue type, such as the muscle of a beating heart. What does this scientific achievement mean for cell therapies and disease models, and how do the new cells compare to the pluripotent stem cells derived without human cloning? Read the full story. Video credit: Cell, Tachibana et al. |
|
|
|
|
|
| |
|
| |
What's New
|
|
Comments - Posted 24 May 2013
Read remarks by Russell Swerdlow about
Savica R et al.
NEWS: A Protein-Based Study of Parkinsonism’s Incidence |
| |
|
Jobs - Posted 24 May 2013
Call for Applications: Group Leader Positions: Paris Institute of Translational Neurosciences, Paris, France. |
| |
|
Jobs - Posted 23 May 2013
PhD Student Position: AlzeCure/University of Gothenburg, Sweden. |
| |
|
Comments - Posted 22 May 2013
Read remarks by Lewis H. Kuller about
Rodrigue KM et al.
NEWS: Controlling Blood Pressure May Lower Amyloid in ApoE4 Carriers |
| |
|
Comments - Posted 22 May 2013
Read remarks by Kathleen Hayden about
Rodrigue KM et al.
NEWS: Controlling Blood Pressure May Lower Amyloid in ApoE4 Carriers |
| |
|
Comments - Posted 22 May 2013
Read remarks by Ashley Bush
NEWS: Larry Sparks, of Alzheimer’s-Cholesterol Fame, Dies at 63 |
| |
|
Comments - Posted 21 May 2013
Read remarks by Barry Greenberg
NEWS: Larry Sparks, of Alzheimer’s-Cholesterol Fame, Dies at 63 |
| |
|
Conferences - Posted 20 May 2013
23rd Neuropharmacology Conference 2013: 7-8 November 2013, Sheraton San Diego Hotel and Marina, San Diego, CA, U.S.A. |
SEE MORE |
Home
Check out our most recent Webinar: 
